Objective: Aim of this paper is to present the design, construction, and modalities of
dissemination of the AutoInflammatory Disease Alliance (AIDA) International Registry for …

Introduction The effectiveness of canakinumab may change according to the different times it
is used after Still's disease onset. This study aimed to investigate whether canakinumab …

Objective Still's disease is more frequently observed in the paediatric context, but a delayed
onset is not exceptional both in the adulthood and in the elderly. However, whether …

Methods A panel was assembled consisting of German rheumatology experts, two patient
representatives from the German national patient organization Rheumaliga, and a delegate …

Background: Biological drugs, mainly interleukin (IL)-1 and IL-6 antagonists, but also tumor
necrosis factor (TNF) inhibitors, have been used in the treatment of adult onset Still's disease …

Background Biotherapy is becoming increasingly important in the treatment of adult-onset
Still's disease (AOSD). The aim of our study was to evaluate the efficacy and safety of …

Background Different patient clusters were preliminarily suggested to dissect the clinical
heterogeneity in Still's disease. Thus, we aimed at deriving and validating disease clusters …

Objective: Adult-onset Still's disease (AOSD) is a rare but clinically well-known polygenic
systemic autoinflammatory disease. In this review, we aim to present frontiers in the …

ABSTRACT Introduction: Adult onset Still's disease (AOSD) is a systemic inflammatory
disorder of unknown etiology, and approximately 60-70% of patients may develop a chronic …

Introduction The treatment of the patients with adult-onset Still's disease (AOSD) remains
largely empirical and it is based on the administration of immunosuppressive drugs. In this …